Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Twelves

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†L A Renfro, A Grothey, D Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorinJ Cassidy, C Twelves, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trialW Scheithauer, J McKendrick, S Begbie, et al.
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
British Journal of Cancer|October 2, 2003
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancerM S Braun, F Adab, C Bradley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
British Journal of Cancer|April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialJ Cassidy, J-Y Douillard, C Twelves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy resultsE Hamilton, M Oliveira, N Turner, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†L A Renfro, A Grothey, D Kerr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorinJ Cassidy, C Twelves, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trialW Scheithauer, J McKendrick, S Begbie, et al.
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
British Journal of Cancer|October 2, 2003
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancerM S Braun, F Adab, C Bradley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
British Journal of Cancer|April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialJ Cassidy, J-Y Douillard, C Twelves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy resultsE Hamilton, M Oliveira, N Turner, et al.
Pageof 8